Company Overview
Senti Biosciences, Inc. operates as a clinical stage biotechnology company dedicated to developing cell and gene therapies engineered with proprietary gene circuit platform technologies for patients suffering from incurable diseases. The company functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, which focuses on the discovery, development, and commercialization of novel therapeutics to address unmet medical needs. As of the latest data, the enterprise holds a market capitalization of $24.61M and reported annual revenue (TTM) of $22,000, with no disclosed employee count available in the current records. These financial figures indicate that the company is a micro-cap entity with minimal revenue generation relative to its market valuation, suggesting a position that relies heavily on future clinical milestones rather than current commercial sales to drive its stock price.
Financial Health
The company reported revenue of $22,000 over the trailing twelve months, while net income stood at -$61,438,000 and EBITDA was -$54,667,000, revealing a significant gap between minimal top-line revenue and substantial operational losses that highlights a cost structure dominated by high research and development expenditures. Free cash flow for the period was -$29,256,000, indicating that the company is currently burning cash to fund its operations and development pipeline, which limits its immediate financial flexibility without additional capital raises or asset monetization. The gross margin is reported at 100.0%, a figure typical for pre-revenue biotechnology firms where manufacturing costs are negligible compared to the lack of sales, while the operating margin of -37,095.5% and profit margin of 0.0% underscore the extreme leverage of fixed costs against a revenue base that is currently negligible. The balance sheet presents a leveraged profile with cash holdings of $16.42M against total debt of $28.89M, resulting in a debt-to-equity ratio of 516.93% which signals a high reliance on equity financing to support its solvency. Despite the heavy debt load, the current ratio of 1.67 suggests that the company maintains sufficient short-term liquid assets to cover its short-term liabilities, providing a baseline of liquidity stability. Return on equity is -218.1% and return on assets is -48.9%, metrics that mathematically reflect the dilutive nature of current operations and the inability to generate positive returns on the capital base during this clinical development phase.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable (N/A) due to the lack of earnings, while the forward P/E is listed as -0.49, implying that the market currently prices the stock based on future expectations of profitability that have not yet materialized in historical data. The price-to-book ratio stands at 4.37, indicating that the market values the company at a significant premium over its net asset book value, likely reflecting the potential value of its intellectual property and pipeline assets rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 1118.51 and an EV/EBITDA of -0.68 further illustrate the speculative nature of the valuation, where the stock price is detached from current revenue generation and negative earnings multiples. The stock has traded between a 52-week high of $5.10 and a 52-week low of $0.79, meaning the current market price sits within this wide volatility range and reflects the high risk premium associated with pre-commercial biotechnology assets. The beta value is not available (N/A), preventing a direct comparison of price volatility relative to the broader market, though the wide 52-week range of $0.79 to $5.10 inherently demonstrates high idiosyncratic volatility typical of small-cap clinical stage firms.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not applicable (N/A) in the current dataset, precluding any analysis of historical expansion rates or the relationship between earnings growth and revenue growth. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company retains all earnings—however negative—to reinvest into its growth initiatives rather than distributing income to shareholders. This reinvestment strategy is consistent with the operational model of a clinical stage biotechnology company, where capital is directed toward advancing product candidates through clinical trials rather than shareholder returns. The overall growth and income profile is characterized by a lack of current income generation and undefined historical growth rates, leaving the company's value entirely contingent on the successful execution of future clinical programs and the eventual commercialization of its lead product candidates utilizing off-the-shelf healthy adult donor derived natural killer cells.